血清铁蛋白与前列腺癌骨转移的关系

Relationship between serum ferritin and bone metastasis of prostate cancer

目的观察前列腺癌骨转移患者血清中血清铁蛋白（SF）的表达及血清白细胞介素-6（IL-6）、可溶性转铁蛋白受体（sTfR）指标的变化，分析3个指标之间的相关性，探讨SF在前列腺癌骨转移中的作用。方法选取前列腺癌骨转移患者25例、前列腺癌无骨转移患者30例和前列腺增生（BPH）患者30例，年龄55—75岁，平均67岁。前列腺癌骨转移前列腺特异抗原（PSA）基线大于20μg／L，范围20．0～1500．0μg／L，中位数138．0μg／L。无骨转移PSA3．5—28．2μg／L，中位数10．2μg／L。BPH组PSA0．3～14．2μg/L，中位数3．7μg/L。清晨空腹抽取静脉血3ml置于乙二胺四乙酸（EDTA）抗凝剂真空管，4℃离心10min，分离出血清，置一80℃冰箱保存。采用竞争性同相酶联免疫分析法（ELISA）分别测定SF、IL-6、sTill的表达。结果SF表达在前列腺癌骨转移组为（330．0±61．9）μg/L，前列腺癌无骨转移组为（140．1±17．1）μg／L，BPH组为（128．3±12．7）μg／L，前列腺癌骨转移组与无骨转移组和BPH组比较差异均有统计学意义（P〈0．05）。骨转移组SF与IL-6[（22．5±22．1）μg／L]、sTfR[（5．7±2．6）μg／L]的表达有明显相关，相关系数分别为0．972、-0．987、0．971，差异均有统计学意义（P〈0．05）。结论前列腺癌骨转移患者的SF表达增高，有助于晚期前列腺癌骨转移诊断以及预后判断。

Objective To observe the changes of serum ferritin （ SF）, interleukin - 6 （ IL - 6）, and soluble transferrin receptor （sTfR） in prostate cancer patients with bone metastasis, analyze the corre- lation among three indexes, and to explore the role of SF in prostate cancer with bone metastasis. Methods From 2011 January to 2014 June, 25 cases of prostate cancer with bone metastasis, 30 cases of prostate cancer without bone metastasis, and 30 patients with benign prostatic hyperplasia （BPH） were included. The age of patients ranged from 55 to 75 years （ mean 67 ）. In the group of prostate cancer with bone me- tastasis, the baseline prostate specific antigen （PSA） was more than 20 μg/L, ranging from 20.0- 1 500 μg/L （mean 138.0 μg/L） , serum PSA ranged from 3.5 -28.2 μg/L （mean 10. 2 μg/L） in the group of prostate cancer without bone metastasis, and serum PSA ranged from 0. 3 - 14.2 μg/L （ mean 3.7 μg/L） in the group of BPH. In the morning fasting venous blood was taken out, and serum was isola- ted. The competitive in- phase enzyme -linked immunoassay （ELISA） was used to determine serum SF, IL - 6 and sTfR. Results The expression of SF was （ 330. 0 ± 61.9 ） μg,/L in prostate cancer with bone metastasis group, （140. 1 ± 17.1 ） μg/L in prostate cancer without bone metastasis group, and （128.3 ± 12. 7） μg/L in BPH grou. There was significant difference between prostate cancer with bone metastasis group and protate cancer without bone metastasis group or BPH group （ P 〈 0. 05 ）. In prostate cancer with bone metastasis group, SF was significantly correlated with IL -6 [ （22. 5 ± 22. 1 ） μg/L] and sTfR [ （5.7 ±2. 6） μg/L] expression with the correlation coefficients being 0. 972, -0. 987, 0. 971 respec- tively （P 〈 0. 05） Conclusion Serum SF expression, which increased in prostate cancer with bone metas- tasis, can be used as a sensitive index for diagnosis and prognosis evaluation of advanced prostate cancer with bone metastasis.